Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 1/2015

01-03-2015 | Interventional Pulmonology (S Maceiras-Luis, Section Editor)

Indwelling pleural catheters

Authors: William D. Jones, Helen E. Davies

Published in: Current Pulmonology Reports | Issue 1/2015

Login to get access

Abstract

Indwelling pleural catheters (IPCs) are increasingly used in clinical practice. They are often accepted as a first-line treatment option for patients with malignant pleural effusion. IPCs are inserted as a day case and afford patients autonomous relief of symptoms in the outpatient setting. They also offer scope for ongoing study, monitoring and treatment of malignant pleural effusion, as well as a role in benign effusion management. This paper provides an overview of the rationale and principles of IPC use, describing practical aspects and outlining potential future developments destined to address current voids in knowledge.
Literature
1.
Sanchez-Armengol A, Rodriguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. Chest. 1993;104(5):1482–5.CrossRefPubMed
2.
Pilling JE, Dusmet ME, Ladas G, Goldstraw P. Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol. 2010;5(10):1544–50.CrossRefPubMed
3.
van Galen KP, Visser HP, van der Ploeg T, Smorenburg CH. Prognostic factors in patients with breast cancer and malignant pleural effusion. Breast J. 2010;16(6):675–7.CrossRefPubMed
4.
Banerjee AK, Willetts I, Robertson JF, Blamey RW. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol. 1994;20(1):33–6.PubMed
5.
Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J. 2007;30(4):759–62.CrossRefPubMed
6.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–92.CrossRefPubMed
7.
Mishra E, Davies H, Lee Y. Malignant pleural disease in lung cancer. In: Spiro S, Janes S, editors. European Respiratory Monograph: Thoracic Malignancies: European Respiratory Society Journals Limited.; 2009. p. 318–35.
8.
West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med. 2006;27(2):335–54.CrossRefPubMed
9.
10.
Marinaccio A, Montanaro F, Mastrantonio M, Uccelli R, Altavista P, Nesti M, et al. Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. Int J Cancer. 2005;115(1):142–7.CrossRefPubMed
11.
Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J. 1989;2(4):366–9.PubMed
12.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014.
13.
Statistics OfN. Cancer Statistics Registrations, England, 2012. Statistical Bulletin: Office for National Statistics [Internet]. 2014:[0–19pp.]
14.
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, Group BPDG. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii32–40.CrossRefPubMed
15.••
Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383–9. This RCT demonstrated there is no significant difference between IPC use and talc pleurodesis at relieving dyspnoea in patients with a malignant pleural effusion. It directly assessed patient related outcome measures. CrossRefPubMed
16.•
Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3):909–15. In this phase III study of 501 patients no significant difference was seen in pleurodesis success between thoracocopic talc poudrage and tube administered talc slurry. CrossRefPubMed
17.
Lee YC, Fysh ET. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol. 2011;6(4):655–7.CrossRefPubMed
18.
Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, et al. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol. 2011;6(4):762–7.CrossRefPubMed
19.
Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer. 1974;33(4):916–22.CrossRefPubMed
20.
Lee YC, Baumann MH, Maskell NA, Waterer GW, Eaton TE, Davies RJ, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest. 2003;124(6):2229–38.CrossRefPubMed
21.
Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004;1:CD002916.PubMed
22.
Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg. 1996;62(6):1655–8.CrossRefPubMed
23.
Terra RM, Junqueira JJ, Teixeira LR, Vargas FS, Pêgo-Fernandes PM, Jatene FB. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest. 2009;136(2):361–8.PubMed
24.
Putnam JB, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86(10):1992–9.
25.
Davies HE, Lee YC, Davies RJ. Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax. 2008;63(7):572–4.CrossRefPubMed
26.
Ferrer J, Montes JF, Villarino MA, Light RW, García-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest. 2002;122(3):1018–27.CrossRefPubMed
27.
Werebe EC, Pazetti R, Milanez de Campos JR, Fernandez PP, Capelozzi VL, Jatene FB, et al. Systemic distribution of talc after intrapleural administration in rats. Chest. 1999;115(1):190–3.CrossRefPubMed
28.
Campos JR, Werebe EC, Vargas FS, Jatene FB, Light RW. Respiratory failure due to insufflated talc. Lancet. 1997;349(9047):251–2.CrossRefPubMed
29.
Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet. 2007;369(9572):1535–9.CrossRefPubMed
30.
Arellano-Orden E, Romero-Falcon A, Juan JM, Ocaña Jurado M, Rodriguez-Panadero F, Montes-Worboys A. Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis. Respiration. 2013;86(3):201–9.CrossRefPubMed
31.
Davies H, Lee Y. Pleurodesis. In: Lee RLaY, editor. Textbook of pleural diseases. 2nd Edition ed: Hodder & Stoughton Ltd; 2008. p. 569–83.
32.
Simoff MJ, Lally B, Slade MG, Goldberg WG, Lee P, Michaud GC, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e455S–97S.CrossRefPubMed
33.
Qureshi RA, Collinson SL, Powell RJ, Froeschle PO, Berrisford RG. Management of malignant pleural effusion associated with trapped lung syndrome. Asian Cardiovasc Thorac Ann. 2008;16(2):120–3.CrossRefPubMed
34.
Dikensoy O, Light RW. Alternative widely available, inexpensive agents for pleurodesis. Curr Opin Pulm Med. 2005;11(4):340–4.CrossRefPubMed
35.••
Bhatnagar R, Reid ED, Corcoran JP, Bagenal JD, Pope S, Clive AO, et al. Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice. Thorax. 2014;69(10):959–61. This is the largest review of IPC use for benign disease.CrossRefPubMed
36.
Davies HE, Rahman NM, Parker RJ, Davies RJ. Use of indwelling pleural catheters for chronic pleural infection. Chest. 2008;133(2):546–9.CrossRefPubMed
37.
DePew ZS, Iqbal S, Mullon JJ, Nichols FC, Maldonado F. The role for tunneled indwelling pleural catheters in patients with persistent benign chylothorax. Am J Med Sci. 2013;346(5):349–52.CrossRefPubMed
38.
Jimenez CA, Mhatre AD, Martinez CH, Eapen GA, Onn A, Morice RC. Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer. Chest. 2007;132(5):1584–90.CrossRefPubMed
39.
Srour N, Potechin R, Amjadi K. Use of indwelling pleural catheters for cardiogenic pleural effusions. Chest. 2013;144(5):1603–8.CrossRefPubMed
40.
Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70–6.CrossRefPubMedCentralPubMed
41.
Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters. Interact Cardiovasc Thorac Surg. 2009;9(6):961–4.CrossRefPubMed
42.
Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest. 2001;119(6):1641–6.CrossRefPubMed
43.
Hunt BM, Farivar AS, Vallières E, Louie BE, Aye RW, Flores EE, et al. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg. 2012;94(4):1053–7. discussion 7–9.CrossRefPubMed
44.•
Fysh ET, Waterer GW, Kendall PA, Bremmer PR, Dina S, Geelhoed E, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012;142(2):394–400. This prospective study compared IPC use and pleurodesis in a 'real-time' hospital setting. CrossRefPubMed
45.
Puri V, Pyrdeck TL, Crabtree TD, Kreisel D, Krupnick AS, Colditz GA, et al. Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg. 2012;94(2):374–9. discussion 9–80.CrossRefPubMedCentralPubMed
46.
Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med. 2010;13(1):59–65.CrossRefPubMedCentralPubMed
47.
Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. Chest. 2014;146(4):991–1000.CrossRefPubMed
48.
Bertolaccini L, Viti A, Gorla A, Terzi A. Home-management of malignant pleural effusion with an indwelling pleural catheter: ten years experience. Eur J Surg Oncol. 2012;38(12):1161–4.CrossRefPubMed
49.
Chalhoub M, Harris K, Castellano M, Maroun R, Bourjeily G. The use of the PleurX catheter in the management of non-malignant pleural effusions. Chron Respir Dis. 2011;8(3):185–91.CrossRefPubMed
50.
Mullon J, Maldonado F. Use of tunneled indwelling pleural catheters for palliation of nonmalignant pleural effusions. Chest. 2011;140(4):996A.CrossRef
51.
52.
Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362–8.CrossRefPubMed
53.
Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol. 2009;35(5):546–51.CrossRefPubMed
54.
Ohm C, Park D, Vogen M, Bendick P, Welsh R, Pursel S, et al. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. Am Surg. 2003;69(3):198–202. discussion.PubMed
55.
Warren WH, Kim AW, Liptay MJ. Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33(1):89–94.CrossRefPubMed
56.
Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. Chest. 2000;118(2):417–21.CrossRefPubMed
57.
Patz EF. Malignant pleural effusions: recent advances and ambulatory sclerotherapy. Chest. 1998;113(1 Suppl):74S–7S.CrossRefPubMed
58.
Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139(6):1419–23.CrossRefPubMed
59.
60.
Tremblay A, Dumitriu S, Stather DR, Maceachern P, Illanes O, Kelly MM. Use of a drug eluting pleural catheter for pleurodesis. Exp Lung Res. 2012;38(9–10):475–82.CrossRefPubMed
61.
Morel A, Mishra E, Medley L, Rahman NM, Wrightson J, Talbot D, et al. Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. Thorax. 2011;66(5):448–9.CrossRefPubMed
62.
Mekhaiel E, Kashyap R, Mullon JJ, Maldonado F. Infections associated with tunnelled indwelling pleural catheters in patients undergoing chemotherapy. J Bronchology Interv Pulmonol. 2013;20(4):299–303.CrossRefPubMed
63.
64.
65.
Fysh ET, Wrightson JM, Lee YC, Rahman NM. Fractured indwelling pleural catheters. Chest. 2012;141(4):1090–4.CrossRefPubMed
66.
Fysh ET, Tremblay A, Feller-Kopman D, Mishra EK, Slade M, Garske L, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest. 2013.
67.
Wu SG, Hu FC, Chang YL, Lee YC, Yu CJ, Chang YC, et al. Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. Eur Respir J. 2013;41(2):417–24.CrossRefPubMed
68.
Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009;20(4):696–702.CrossRefPubMed
69.
Koegelenberg CF, Diacon AH, Bolliger CT. Parapneumonic pleural effusion and empyema. Respiration. 2008;75(3):241–50.CrossRefPubMed
70.
Mandal AK, Thadepalli H, Chettipally U. Outcome of primary empyema thoracis: therapeutic and microbiologic aspects. Ann Thorac Surg. 1998;66(5):1782–6.CrossRefPubMed
71.
Lin YC, Chen HJ, Liu YH, Shih CM, Hsu WH, Tu CY. A 30-month experience of thoracic empyema in a tertiary hospital: emphasis on differing bacteriology and outcome between the medical intensive care unit (MICU) and medical ward. South Med J. 2008;101(5):484–9.CrossRefPubMed
72.
Chen KY, Hsueh PR, Liaw YS, Yang PC, Luh KT. A 10-year experience with bacteriology of acute thoracic empyema: emphasis on Klebsiella pneumoniae in patients with diabetes mellitus. Chest. 2000;117(6):1685–9.CrossRefPubMed
73.
Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest. 2007;131(4):1232–4.CrossRefPubMed
74.
75.
Thomas R, Budgeon CA, Kuok YJ, Read C, Fysh ET, Bydder S, et al. Catheter tract metastasis associated with indwelling pleural catheters. Chest. 2014;146(3):557–62.CrossRefPubMed
76.
Srour N, Amjadi K, Forster A, Aaron S. Management of malignant pleural effusions with indwelling pleural catheters or talc pleurodesis. Can Respir J. 2013;20(2):106–10.PubMedCentralPubMed
77.
Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol. 2001;12(2):201–8.CrossRefPubMed
78.
Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med. 2008;178(1):50–9.CrossRefPubMed
79.
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186(6):487–92.CrossRefPubMed
80.
Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer. 2010;103(5):629–41.CrossRefPubMedCentralPubMed
81.
Wang T, Lv M, Shen S, Zhou S, Wang P, Chen Y, et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS ONE. 2012;7(8):e43268.CrossRefPubMedCentralPubMed
82.
Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013;133(3):645–52.CrossRefPubMed
83.
Chen D, Sun Y, Yuan Y, Han Z, Zhang P, Zhang J, et al. miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion. PLoS Genet. 2014;10(2):e1004177.CrossRefPubMedCentralPubMed
84.
Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007;13(15 Pt 1):4456–66.CrossRefPubMed
85.
Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther. 2010;18(4):852–60.CrossRefPubMedCentralPubMed
86.
Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, et al. A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011;184(12):1395–9.CrossRefPubMedCentralPubMed
Metadata
Title
Indwelling pleural catheters
Authors
William D. Jones
Helen E. Davies
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 1/2015
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-015-0104-x

Other articles of this Issue 1/2015

Current Pulmonology Reports 1/2015 Go to the issue

Pleural Diseases and Mesothelioma (G Lee, Section Editor)

Chemical pleurodesis for first presentation of primary spontaneous pneumothorax

Sleeping and Breathing (T Lee-Chiong, Section Editor)

Sleep-disordered breathing as a modifiable risk factor for cardiovascular disease

Pleural Diseases and Mesothelioma (G Lee, Section Editor)

Discovery of new biomarkers for malignant mesothelioma

Pleural Diseases and Mesothelioma (G Lee, Section Editor)

IgG4-related pleural disease

Pleural Diseases and Mesothelioma (C Gary Lee, Section Editor)

Adjunct strategies to enhance the efficacy of indwelling pleural catheters

Sleeping and Breathing (T Lee-Chiong, Section Editor)

Obesity hypoventilation syndrome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits